期刊文献+

索拉非尼治疗晚期肾癌的临床观察 被引量:13

Clinical study of sorafenib for patients with advanced renal cell carcinoma
原文传递
导出
摘要 目的分析和评价索拉非尼治疗晚期肾癌的疗效和安全性。方法回顾性分析2007年9月至2012年4月我院诊断明确的晚期肾细胞癌患者33例,男26例,女7例。年龄32~83岁,中位年龄69岁。其中透明细胞癌30例,乳头状细胞癌2例,未分化癌l例。采用口服索拉非尼400mg,2次/d,单药治疗,持续治疗至肿瘤进展或出现不可耐受的不良反应。主要观察终点为客观有效率、临床获益率、中位生存时间、中位无疾病进展时间和不良反应发生率。结果可评价疗效患者33例。其中部分缓解8例(24%),疾病稳定19例(58%),疾病进展6例(18%),疾病控制率82%,中位生存时间16.5个月,中位无疾病进展时间10.2个月。1年生存率67%。常见不良反应包括手足皮肤病变20例(6l%)、腹泻15例(46%)、高血压7例(21%)。多数不良反应于服药2周左右出现,持续时间不等,经对症治疗后缓解,未影响服药。结论索拉非尼治疗晚期肾癌的疗效良好,大部分不良反应患者可耐受。 Objective To evaluate the efficacy and safety of sorafenib in the treatment of advanced renal cell carcinoma. Methods The clinical date of 33 patients with advanced renal cell carcinoma from September 2007 to April 2012 was reviewed retrospectively. 26 were males and 7 were females, with an average age of 69 years. Pathological diagnosis showed 30 clear cell RCCs, 2 papillary RCCs, and 1 unclas- sifted RCC. These patients were treated by sorafenib 400 mg twice a day until intolerable toxicity or disease progression. The primary end points were objective response rate, clinical benefit rate, median survival time, median progression-free survival and the incidence of adverse reaction. Results All patients were evaluable for response and toxicity, with 8 patients (24%) of partial remission, 19 cases (58%) of stable disease, and 6 cases ( 18% ) of disease progression. The disease control rate was 82% , the median progres- sion-free survival was 10.2 months, while the median survival time was 16.5 months. The common adverse reactions included hand-foot skin reaction (61%), diarrhea (46%), hypertension (21%). Most adverse reactions occurred around the second week after drug therapy, with the duration unequal. The majority of ad- verse reactions could be released by symptomatic treatment, which did not affect the medication. Conclusion Sorafenib has good short term efficacy for patients with advanced renal cell carcinoma, and most adverse reactions were tolerable.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2013年第5期340-342,共3页 Chinese Journal of Urology
关键词 索拉非尼 晚期肾癌 靶向治疗 Sorafenib Advanced renal cell carcinoma Targeted therapy
  • 相关文献

参考文献11

二级参考文献72

  • 1高健刚 李汉忠.转移性肾细胞癌分子靶向治疗的进展[J].中华泌尿外科杂志,2007,18:786-788.
  • 2Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125-134.
  • 3Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356: 115-124.
  • 4Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 2007, 356: 2271-2281.
  • 5Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase Ⅲ trial. Lancet, 2007, 370: 2103-2111.
  • 6Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982, 5: 649-655.
  • 7Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol, 2006, 22: 1363-1369.
  • 8Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol, 2008, 53: 376-381.
  • 9Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol, 2007, 8: 15-27.
  • 10Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs, 2003, 4: 757-763.

共引文献77

同被引文献151

  • 1兰晓鹏,蒋伟,孙桢,王正,金讯波,夏庆华.各年龄段(青年、中年、老年)肾癌患者临床特征及诊治分析[J].泌尿外科杂志(电子版),2013,5(4):4-8. 被引量:13
  • 2杜林栋,王文营.肾癌的分子靶向治疗[J].临床泌尿外科杂志,2007,22(10):721-724. 被引量:4
  • 3Harshman LC,Yu RJ,Allen GI,et al. Surgical outcomes and compli - cations associated with presurglcal tyrosine kinase inhibition for advanced renal cell carcinoma (RCC) [J]. Urol. Oncol, 2013,31: 379-385.18.
  • 4Guo J, Huang YR,Zhang X,et al.Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy:an open-label phase lb study[J]. BMC Cancer,2013,13:136.
  • 5National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer.2013.V1.May 12th,2012.
  • 6Procopio G, Bellmunt J, Dutcher J, et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma:results from a large pooled analysis[J].Br J Cancer,2013,108:311-318.
  • 7Bergmann L,Goebell PJ,Kube U,et al.Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study[J]. Oncology,2013,36:95-100.
  • 8McRonald FE,Morris MR,Gentle D,et al.CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma[J].Mol Cancer,2009,3:31-41.
  • 9Sata Y,Yoshizato T,Shiraishi Y,et al.Integrated molecular analysis of clear-cell renal cell carcinoma[J].Nat Genet,2013,45:860-867.
  • 10Vaupel P,Mayer A.Hypoxia in cancer:significance and impact on clinical outcome[J].Cancer Metastasis Rev,2007,26:225-239.

引证文献13

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部